StockNews.AI
KALV
Benzinga
5 hrs

KalVista Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

1. KALV to report Q1 earnings on Sept. 11 with expected losses. 2. Projected revenue for Q1 is $2.09 million. 3. Company's shares recently fell 2.2% to $15.61. 4. Analysts maintain bullish ratings with price targets up to $28. 5. Orphan designation for Sebetralstat maintained in the EU.

4m saved
Insight
Article

FAQ

Why Bullish?

Despite projected losses, strong analyst ratings suggest potential recovery. Historical patterns show bullish sentiment can support stock prices even with losses.

How important is it?

Analyst expectations for recovery outweigh immediate negative earnings outlook, indicating significant market interest.

Why Short Term?

Earnings results can swiftly impact stock price, as seen in prior earnings releases influencing immediate trading behavior.

Related Companies

Related News